



# **Tuberculosis Country Profile 2021 Bangladesh**

*Source: Global tuberculosis report 2021. Geneva: World Health Organization*

*Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.*

# Tuberculosis profile: Bangladesh

Population 2020: 165 million

## Estimates of TB burden\*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	360 000 (270 000-462 000)	218 (164-281)
HIV-positive TB incidence	710 (370-1 200)	0.43 (0.22-0.71)
HIV-negative TB mortality	44 000 (30 000-61 000)	27 (18-37)
HIV-positive TB mortality	170 (120-240)	0.11 (0.07-0.15)

## Universal health coverage and social protection\*

TB treatment coverage (notified/estimated incidence), 2020	64% (50-85)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	13% (7-19)

## TB case notifications, 2020

Total new and relapse	230 081
- % tested with rapid diagnostics at time of diagnosis	22%
- % with known HIV status	2.8%
- % pulmonary	81%
- % bacteriologically confirmed <sup>^</sup>	76%
- % children aged 0-14 years	4%
- % women (aged ≥15 years)	42%
- % men (aged ≥15 years)	54%
Total cases notified	230 880

## TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	84	1.3%
- on antiretroviral therapy	82	98%

## Drug-resistant TB care\*\*, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases <sup>^</sup>	35%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases <sup>^</sup>	98%
Laboratory-confirmed cases - MDR/RR-TB <sup>^^</sup>	1 113
Patients started on treatment - MDR/RR-TB <sup>^^^</sup>	1 027
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB <sup>^^</sup>	67
Patients started on treatment - pre-XDR-TB or XDR-TB <sup>^^^</sup>	52
MDR/RR-TB cases tested for resistance to any fluoroquinolone	736

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	95%	289 863
Previously treated cases, excluding relapse, registered in 2019	88%	1 347
HIV-positive TB cases registered in 2019	71%	120
MDR/RR-TB cases started on second-line treatment in 2018	74%	1 147
XDR-TB cases started on second-line treatment in 2018	86%	7

## TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	49% (45-54)

## TB financing

National TB budget, 2021 (US\$ millions)	157
- Funding source, domestic	35%
- Funding source, international	25%
- unfunded	39%


## Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




## HIV-negative TB mortality

(Rate per 100 000 population per year)




## Incidence, Notified cases by age group and sex, 2020

(Number)




## Cases attributable to five risk factors, 2020

(Number)



## Total budget

(US\$ millions)



\* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

\*\* RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

<sup>^</sup> Calculated for pulmonary cases only

<sup>^^</sup> Includes cases with unknown previous TB treatment history

<sup>^^^</sup> Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed